Recombinant human TSH increases uptake and effective half-life of radioiodine in thyroid hormone secreting metastases of follicular thyroid cancer

Exp Clin Endocrinol Diabetes. 2012 Mar;120(3):160-3. doi: 10.1055/s-0031-1299710. Epub 2012 Feb 10.

Abstract

Follicular thyroid cancer with thyroid hormone secreting metastases is an extremely rare condition, with only a few cases reported world-wide. We here present the case of a 64-year-old female patient affected by follicular thyroid cancer with extensive thyroid hormone secreting metastases leading to TSH-suppression. We have also summarized the relevant diagnostic and therapeutic approaches and describe, for the first time, the effects of rhTSH-application in this rare tumor entity. In this patient, we found that rhTSH increased ¹³¹I-uptake into the thyroid hormone secreting metastases and prolonged the effective half-life of ¹³¹I. These effects of rhTSH should be considered when fixed activities of ¹³¹I are prescribed.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma, Follicular
  • Combined Modality Therapy
  • Female
  • Half-Life
  • Humans
  • Iodine Radioisotopes / pharmacokinetics*
  • Iodine Radioisotopes / therapeutic use
  • Middle Aged
  • Neoplasm Metastasis
  • Thyroid Hormones / metabolism*
  • Thyroid Neoplasms / metabolism*
  • Thyroid Neoplasms / pathology
  • Thyroid Neoplasms / radiotherapy*
  • Thyrotropin Alfa / administration & dosage
  • Thyrotropin Alfa / pharmacology*
  • Treatment Outcome
  • Up-Regulation / drug effects

Substances

  • Iodine Radioisotopes
  • Thyroid Hormones
  • Thyrotropin Alfa